Kevin J Clerkin1, Maryjane A Farr1, Susan W Restaino1, Emmanuel Zorn2, Farhana Latif1, Elena R Vasilescu3, Charles C Marboe3, Paolo C Colombo1, Donna M Mancini4. 1. Department of Medicine, Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, New York. 2. Columbia Center for Translational Immunology, Columbia University College of Physicians and Surgeons, New York, New York. 3. Department of Pathology and Cell Biology, Columbia University College of Physicians and Surgeons, New York, New York. 4. Department of Medicine, Division of Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: donna.mancini@mountsinai.org.
Abstract
BACKGROUND: Donor-specific anti-HLA antibodies (DSA) are common after heart transplantation and are associated with rejection, cardiac allograft vasculopathy, and mortality. A noninvasive diagnostic test for pathologic antibody-mediated rejection (pAMR) does not exist. METHODS: From January 1, 2010, through August 31, 2013, 221 consecutive adult patients underwent heart transplantation and were followed through October 1, 2015. The primary objective was to determine whether the presence of DSA could detect AMR at the time of pathologic diagnosis. Secondary analyses included association of DSA (stratified by major histocompatibility complex class and de novo status) during AMR with new graft dysfunction, graft loss (mortality or retransplantation), and development of cardiac allograft vasculopathy. RESULTS: During the study period, 69 patients (31.2%) had DSA (24% had de novo DSA), and there were 74 episodes of pAMR in 38 patients. Sensitivity of DSA at any mean fluorescence intensity to detect concurrent pAMR was only 54.3%. The presence of any DSA during pAMR increased the odds of graft dysfunction (odds ratio = 5.37; 95% confidence interval [CI], 1.34-21.47; p = 0.018), adjusting for age, sex, and timing of AMR. Circulating class II DSA after transplantation increased risk of future pAMR (hazard ratio = 2.97; 95% CI, 1.31-6.73; p = 0.009). Patients who developed de novo class II DSA had 151% increased risk of graft loss (contingent on 30-day survival) compared with patients who did not have DSA (95% CI, 1.11-5.69; p = 0.027). CONCLUSIONS: DSA were inadequate to diagnose pAMR. Class II DSA provided prognostic information regarding future pAMR, graft dysfunction with pAMR, and graft loss.
BACKGROUND:Donor-specific anti-HLA antibodies (DSA) are common after heart transplantation and are associated with rejection, cardiac allograft vasculopathy, and mortality. A noninvasive diagnostic test for pathologic antibody-mediated rejection (pAMR) does not exist. METHODS: From January 1, 2010, through August 31, 2013, 221 consecutive adult patients underwent heart transplantation and were followed through October 1, 2015. The primary objective was to determine whether the presence of DSA could detect AMR at the time of pathologic diagnosis. Secondary analyses included association of DSA (stratified by major histocompatibility complex class and de novo status) during AMR with new graft dysfunction, graft loss (mortality or retransplantation), and development of cardiac allograft vasculopathy. RESULTS: During the study period, 69 patients (31.2%) had DSA (24% had de novo DSA), and there were 74 episodes of pAMR in 38 patients. Sensitivity of DSA at any mean fluorescence intensity to detect concurrent pAMR was only 54.3%. The presence of any DSA during pAMR increased the odds of graft dysfunction (odds ratio = 5.37; 95% confidence interval [CI], 1.34-21.47; p = 0.018), adjusting for age, sex, and timing of AMR. Circulating class II DSA after transplantation increased risk of future pAMR (hazard ratio = 2.97; 95% CI, 1.31-6.73; p = 0.009). Patients who developed de novo class II DSA had 151% increased risk of graft loss (contingent on 30-day survival) compared with patients who did not have DSA (95% CI, 1.11-5.69; p = 0.027). CONCLUSIONS:DSA were inadequate to diagnose pAMR. Class II DSA provided prognostic information regarding future pAMR, graft dysfunction with pAMR, and graft loss.
Authors: Susan Stewart; Gayle L Winters; Michael C Fishbein; Henry D Tazelaar; Jon Kobashigawa; Jacki Abrams; Claus B Andersen; Annalisa Angelini; Gerald J Berry; Margaret M Burke; Anthony J Demetris; Elizabeth Hammond; Silviu Itescu; Charles C Marboe; Bruce McManus; Elaine F Reed; Nancy L Reinsmoen; E Rene Rodriguez; Alan G Rose; Marlene Rose; Nicole Suciu-Focia; Adriana Zeevi; Margaret E Billingham Journal: J Heart Lung Transplant Date: 2005-06-20 Impact factor: 10.247
Authors: Eric K Ho; George Vlad; Elena Rodica Vasilescu; Ludwika de la Torre; Adriana I Colovai; Elizabeth Burke; Mario Deng; Joseph Schwartz; Charles Marboe; Donna Mancini; Gerhard Opelz; Nicole Suciu-Foca Journal: Hum Immunol Date: 2010-11-10 Impact factor: 2.850
Authors: Gerald J Berry; Margaret M Burke; Claus Andersen; Patrick Bruneval; Marny Fedrigo; Michael C Fishbein; Martin Goddard; Elizabeth H Hammond; Ornella Leone; Charles Marboe; Dylan Miller; Desley Neil; Doris Rassl; Monica P Revelo; Alexandra Rice; E Rene Rodriguez; Susan Stewart; Carmela D Tan; Gayle L Winters; Lori West; Mandeep R Mehra; Annalisa Angelini Journal: J Heart Lung Transplant Date: 2013-12 Impact factor: 10.247
Authors: J D Smith; N R Banner; I M Hamour; M Ozawa; A Goh; D Robinson; P I Terasaki; M L Rose Journal: Am J Transplant Date: 2011-01-10 Impact factor: 8.086
Authors: J F George; J K Kirklin; T W Shroyer; D C Naftel; R C Bourge; D C McGiffin; C White-Williams; T Noreuil Journal: J Heart Lung Transplant Date: 1995 Sep-Oct Impact factor: 10.247
Authors: E F Reed; P Rao; Z Zhang; H Gebel; R A Bray; I Guleria; J Lunz; T Mohanakumar; P Nickerson; A R Tambur; A Zeevi; P S Heeger; D Gjertson Journal: Am J Transplant Date: 2013-06-13 Impact factor: 8.086
Authors: Kevin J Clerkin; Susan W Restaino; Emmanuel Zorn; Elena R Vasilescu; Charles C Marboe; Donna M Mancini Journal: J Heart Lung Transplant Date: 2016-05-06 Impact factor: 10.247
Authors: A Loupy; C Toquet; P Rouvier; T Beuscart; M C Bories; S Varnous; R Guillemain; S Pattier; C Suberbielle; P Leprince; C Lefaucheur; X Jouven; P Bruneval; J P Duong Van Huyen Journal: Am J Transplant Date: 2015-11-20 Impact factor: 8.086
Authors: Xuedong Wei; Nicole M Valenzuela; Maura Rossetti; Rebecca A Sosa; Jessica Nevarez-Mejia; Gregory A Fishbein; Arend Mulder; Jayeeta Dhar; Karen S Keslar; William M Baldwin; Robert L Fairchild; Jianquan Hou; Elaine F Reed Journal: Am J Transplant Date: 2020-05-22 Impact factor: 8.086
Authors: A I Dipchand; S Webber; K Mason; B Feingold; C Bentlejewski; W T Mahle; R Shaddy; C Canter; E D Blume; J Lamour; W Zuckerman; H Diop; Y Morrison; B Armstrong; D Ikle; J Odim; A Zeevi Journal: Am J Transplant Date: 2018-03-24 Impact factor: 8.086
Authors: Josef Stehlik; Brian Armstrong; David A Baran; Nancy D Bridges; Anil Chandraker; Robert Gordon; Teresa De Marco; Michael M Givertz; Alain Heroux; David Iklé; Judson Hunt; Abdallah G Kfoury; Joren C Madsen; Yvonne Morrison; Erika Feller; Sean Pinney; Sudipta Tripathi; Peter S Heeger; Randall C Starling Journal: Am J Transplant Date: 2019-01-22 Impact factor: 8.086
Authors: Carrie L Butler; Michelle J Hickey; Ning Jiang; Ying Zheng; David Gjertson; Qiuheng Zhang; Ping Rao; Gregory A Fishbein; Martin Cadeiras; Mario C Deng; Hector L Banchs; Guillermo Torre; David DeNofrio; Howard J Eisen; Jon Kobashigawa; Randall C Starling; Abdallah Kfoury; Adrian Van Bakel; Gregory Ewald; Ivan Balazs; Arnold S Baas; Daniel Cruz; Reza Ardehali; Reshma Biniwale; Murray Kwon; Abbas Ardehali; Ali Nsair; Bryan Ray; Elaine F Reed Journal: Am J Transplant Date: 2020-04-26 Impact factor: 8.086
Authors: P R Aguilar; D Carpenter; J Ritter; R D Yusen; C A Witt; D E Byers; T Mohanakumar; D Kreisel; E P Trulock; R R Hachem Journal: Am J Transplant Date: 2017-11-11 Impact factor: 8.086